Today 07:00
Surgical Innovations Group plc
("Surgical Innovations", the "Company", or the "Group")
Elemental secures MIS3 Framework
Reinforces long-standing position as a trusted supplier within the MIS sector
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), announces that its wholly owned subsidiary, Elemental Healthcare Ltd ("Elemental") has been awarded a place on the NHS Minimally Invasive Surgery 3 ("MIS3") framework agreement for an initial period of two years, commencing on 10 August 2026.
This follows the Group's successful participation in the previous NHS MIS1 and MIS2 framework agreements, providing customers with greater product choice. This win reinforces Elemental Healthcare's long-standing position as a trusted supplier within the minimally invasive surgery sector, with its cost-effective procedure-specific surgical instruments.
The MIS3 framework provides streamlined access to NHS procurement channels via NHS Supply Chain, supporting efficient purchasing processes for NHS trusts across the UK. Currently, over 60% of Elemental Healthcare's sales are driven through this key framework, highlighting its strategic importance to the business and illustration of the trusted supplier they are, although it should be noted that this inclusion does not guarantee sales.
In addition to MIS3, Elemental Healthcare continues to hold equivalent framework agreements across Scotland and Wales, ensuring broad national coverage and access across the UK healthcare system, helping surgeons nationwide with their minimal invasive surgery procedures.
Commenting on the award, David Marsh, CEO of Surgical Innovations, said: "This framework award represents a significant achievement for the Group, enabling us to continue to compete effectively in this critical and growing healthcare sector. The Group remains focused on delivering high-quality products and services to NHS partners and looks forward to continuing its strong track record within the minimally invasive surgery market."
For further information please contact:
Surgical Innovations Group plc | www sigroupplc com | ||
David Marsh, CEO | Tel: 0113 230 7597 | ||
David Anderson, CFO |
| ||
|
| ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
Peter Steel / Graham Hertrich / Anastassiya Eley |
| ||
| |||
Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | ||
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company's Resposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

Further information
Further details of the Group's businesses and products are available on the following websites:
www.sigroupplc.com
www.surginno.com
www.elementalhealthcare.co.uk
To receive regular updates by email, please contact si@walbrookpr.com
Follow the stocks